Calcium pyrophosphate deposition disease

Calcium pyrophosphate deposition (CPPD) disease is a benign crystal-induced arthropathy caused by the deposition of calcium pyrophosphate (CPP) crystals within joints and periarticular soft tissues.[1] In the maxillofacial region, the temporomandibular joint (TMJ) is the nearly exclusive site of involvement, where the disease most commonly manifests as the tophaceous variant — a tumoral mass of aggregated CPP crystals surrounding the condylar head.[2][3] Pathogenesis centers on excess extracellular inorganic pyrophosphate, generated from ATP via the ANKH transmembrane transporter and ectonucleotide pyrophosphatase 1 (ENPP1), which complexes with calcium in the cartilaginous matrix to form CPP crystals.[1][4] These crystals activate the NLRP3 inflammasome and directly damage cartilage through matrix metalloproteinase induction.[1] On imaging, the signature finding is a granular or amorphous calcified mass in the TMJ region, less dense than cortical bone, often with erosive changes of the condyle.[5][6] Definitive diagnosis requires crystal identification; management ranges from conservative anti-inflammatory therapy to surgical excision depending on lesion extent.[3][7]

• Calcium pyrophosphate deposition (CPPD) disease is the current preferred umbrella term for all symptomatic presentations, per the 2023 ACR/EULAR classification criteria and the 2026 G-CAN consensus nomenclature.[8][9]
• Acute CPP crystal arthritis replaces the older term "pseudogout" for acute inflammatory episodes; chronic CPP crystal arthritis denotes chronic arthropathy associated with CPP crystals.[1][9]
• Chondrocalcinosis is now defined strictly as a radiographic descriptor — calcification in joint cartilage consistent with CPPD on conventional radiography — and should not be used as a disease name.[4][9]
• Tophaceous pseudogout (or tumoral CPPD) remains in common use for the mass-forming variant that predominates in the TMJ, though "pseudogout" received no support in the G-CAN nomenclature exercise.[2][9]
• Obsolete terms include "calcium pyrophosphate dihydrate deposition disease" (CPPDD) and "pyrophosphate arthropathy".[1][10]

• CPPD is predominantly a disease of aging; chondrocalcinosis prevalence doubles with each decade over 60 years and reaches approximately 44% in those older than 84 years on radiographic surveys of the knee, pelvis, and wrist.[1]
• Sex and BMI are not established risk factors for CPPD overall.[4]
• TMJ involvement is rare. Fewer than 50 cases of CPPD affecting the TMJ had been reported in the English literature as of 2019. However, the TMJ is the most common site for the tophaceous (tumoral) variant of CPPD.[2]
• In TMJ-CPPD, the age distribution is broad (38–89 years; median ~57.5 years), with equal sex distribution and no side predilection.[2]
• Associated metabolic conditions — primary hyperparathyroidism, hereditary hemochromatosis, hypomagnesemia, and hypophosphatasia — are well-established risk factors and may be overrepresented in younger patients.[1][4]

Presentation and symptoms

TMJ-CPPD presents in two principal patterns:

• Tophaceous (tumoral) form: The most common TMJ presentation. Approximately 80% of reported TMJ cases present as a palpable preauricular mass, often painless or mildly symptomatic. Symptoms, when present, include:[2]
  • Pain and swelling over the periauricular region
  • Trismus and limited mouth opening
  • Malocclusion (open bite on the affected side)
  • Joint clicking
  • Conductive hearing loss from mass effect on the external auditory canal[2][7]
• Acute inflammatory form (acute CPP crystal arthritis): Less commonly reported in the TMJ; presents as sudden-onset painful joint swelling mimicking septic arthritis or internal derangement.[11]

Tempo and complications

The tophaceous form typically follows an indolent course over months to years. Progressive condylar destruction and extension into the infratemporal fossa or skull base may occur.[5][12] Erosion into the middle cranial fossa has been reported in a small number of cases.[13] TMJ-CPPD is frequently isolated to the TMJ without other joint involvement, although concurrent chondrocalcinosis at other sites (particularly the knee) is occasionally identified on screening.[3][14]

Red flags

The clinical and radiographic presentation frequently mimics malignancy — chondrosarcoma is the most common preoperative misdiagnosis.[7][15] Any calcified TMJ mass in a patient older than 50 years should prompt consideration of CPPD alongside neoplastic entities.

Location and distribution

CPPD in the maxillofacial region is essentially confined to the TMJ. The calcified deposits are centered on the condylar head and joint space, involving the periarticular and intraarticular compartments.[2][5] Unilateral involvement is the rule in reported cases, with no side predilection.[2] Extension beyond the joint into the infratemporal fossa and toward the skull base occurs in advanced tophaceous disease.[5][12]

Periphery and shape

• On panoramic radiography, tophaceous CPPD appears as an irregular to lobulated radiopaque mass in the supracondylar region, often partially obscured by superimposition of the skull base.[5][15]
• Margins are typically ill-defined and blend with adjacent soft tissue, lacking a distinct corticated border.[15]
• Smaller deposits may appear as punctate or linear calcifications within the joint space or disc region.[11]

Internal architecture

• The hallmark is granular, stippled, or amorphous calcification that is less dense than cortical bone. This density characteristic is a key consensus-defined feature of CPP deposits across all imaging modalities.[5][6]
• Calcification may range from finely granular to coarsely aggregated, depending on the volume of crystal deposition.[5][12]
• Unlike the ring-and-arc pattern of chondroid matrix mineralization seen in synovial chondromatosis or chondrosarcoma, CPPD calcification lacks organized chondroid architecture.[16][17]
• On CBCT, the granular calcified mass is better delineated than on panoramic radiography, allowing assessment of the three-dimensional extent and density of the deposits relative to the condyle.[5][12]

Effects on teeth and adjacent structures

• Condylar erosion and destruction is present in the majority of reported TMJ-CPPD cases; only a small minority show an intact condyle. Erosive changes range from surface irregularity to near-complete resorption of the condylar head.[11][12]
• The articular eminence and glenoid fossa may show erosion or sclerotic remodeling.[12][13]
• Malocclusion results from condylar destruction or mass effect displacing the mandible.[7][12]
• Teeth are not directly affected; the disease process is confined to the joint and periarticular tissues.

Extent and cortical involvement

• In the tophaceous form, the calcified mass may surround the condylar head circumferentially and extend superiorly through the glenoid fossa into the middle cranial fossa.[13]
• Lateral extension into the infratemporal fossa is well documented.[12]
• CBCT and medical CT are essential for mapping the full extent of disease, particularly when skull base involvement is suspected.[5][12]

Variants

• Non-tophaceous TMJ-CPPD: Rare reports describe minimal radiographic findings — subtle disc calcification or small periarticular calcific foci without mass formation, resembling internal derangement on initial imaging. These cases may lack visible calcification on panoramic radiography and require advanced imaging or arthroscopic biopsy for diagnosis.[11][14][18]

Medical CT

CT is the optimal modality for characterizing tophaceous CPPD of the TMJ.[2] It demonstrates the granular calcified mass surrounding the condyle with density less than cortical bone, precisely delineates condylar erosion, and maps extension into the infratemporal fossa and skull base — findings that directly influence surgical planning.[5][6][12] Dual-energy CT (DECT) can further differentiate CPP deposits from other calcium crystal species based on material decomposition characteristics.[6][19]

MRI

MRI has limited sensitivity for detecting calcification and is generally inferior to CT for CPPD diagnosis.[1][19] However, MRI may reveal joint effusion, synovial thickening, and internal derangement patterns. In one reported TMJ case, MRI demonstrated disc displacement without reduction but failed to identify the underlying crystal deposition, which was only confirmed at arthroscopy and biopsy.[18] MRI may be useful as a complementary study when soft-tissue characterization or exclusion of a solid neoplasm is needed.[20]

The principal diagnostic challenge is distinguishing tophaceous CPPD from neoplastic and other non-neoplastic calcified masses of the TMJ. Malignancy — particularly chondrosarcoma — is the most frequent preoperative misdiagnosis.[7][15]

The highest-risk diagnostic pitfall is misidentifying tophaceous CPPD as chondrosarcoma, leading to unnecessarily aggressive surgery. When a calcified TMJ mass is encountered in a patient older than 50 years, fine-needle aspiration cytology or incisional biopsy with polarized light microscopy should be performed before definitive resection to confirm crystal identity.[7]

Microscopic findings

• The diagnostic hallmark is deposition of CPP crystals — rod-shaped and rhomboid forms with blunt ends — within a background of amorphous basophilic calcified material.[5][12]
• Under compensated polarized light microscopy, CPP crystals demonstrate weak positive birefringence, distinguishing them from the strong negative birefringence of monosodium urate crystals.[7][23]
• The surrounding tissue typically contains macrophages, multinucleated foreign-body giant cells, and scattered benign chondrocytes within a fibrous or chondroid stroma.[7]

Confirmatory techniques

• When crystal morphology is equivocal, X-ray diffraction and Fourier transform infrared spectroscopy provide definitive identification of CPP crystal composition.[5]
• Scanning electron microscopy with energy-dispersive X-ray spectroscopy has also been used to confirm the calcium-to-phosphorus ratio characteristic of CPP crystals.[12]

Radiologic-pathologic correlation

The granular calcified mass seen on CT corresponds to dense aggregates of CPP crystals embedded in fibrous tissue with giant cell reaction. The less-than-cortical-bone density on imaging reflects the crystalline rather than osseous nature of the deposits.[5][6] Condylar erosion seen radiographically correlates with crystal-induced inflammation and direct catabolic effects of CPP crystals on cartilage and bone.[1]

Fine-needle aspiration cytology

FNA — including ultrasound-guided FNA — can establish the diagnosis preoperatively by demonstrating birefringent CPP crystals amid giant cells and macrophages, potentially avoiding open biopsy.[2][7]

Workup and referral

• Metabolic screening is indicated, particularly in patients younger than 60 years: serum calcium, phosphate, parathyroid hormone, magnesium, alkaline phosphatase, iron studies (iron, transferrin, ferritin), and consideration of HFE gene testing if iron overload is suspected.[1][4]
• Rheumatology referral is recommended to evaluate for polyarticular CPPD and manage systemic disease.[4][14]
• Screening radiographs of the knees and wrists may reveal concurrent chondrocalcinosis.[14]

Treatment

Treatment depends on the clinical form and extent of disease:

• Conservative management:
  • For mild or non-tophaceous TMJ-CPPD, NSAIDs, colchicine, or short-course systemic glucocorticoids may control symptoms.[7][25][26]
  • Arthroscopic lavage (joint wash) is an option when disease is limited to the synovium.[7]
  • Arthroscopic-assisted biopsy can simultaneously confirm diagnosis and provide therapeutic benefit.[14]
• Surgical excision:
  • Temporomandibular arthrotomy with removal of the calcified mass is the most commonly reported treatment for tophaceous TMJ-CPPD.[3][11]
  • Careful removal of crystal deposits with preservation of remaining joint structures is preferred when the condyle is not severely destroyed.[11]
  • Extensive disease with skull base erosion requires multidisciplinary surgical planning.[13]
• No disease-modifying therapy currently exists that dissolves CPP crystals or prevents their formation.[25][27]

Prognosis and recurrence

• Tophaceous CPPD of the TMJ is a benign condition, and surgical excision generally provides symptomatic relief.[3][15]
• Recurrence data are limited given the rarity of TMJ involvement; however, CPPD is a systemic metabolic disorder, and crystal re-accumulation remains possible.[27]
• Correction of underlying metabolic abnormalities (e.g., hyperparathyroidism, hypomagnesemia) may reduce the risk of disease progression, though CPPD often persists even after metabolic correction.[1]

Familial CPPD

CPPD disease presenting before age 60 should prompt inquiry about affected family members. Gain-of-function mutations in the ANKH gene (CCAL2 locus, chromosome 5p) cause autosomal dominant familial CPPD with premature, polyarticular chondrocalcinosis.[1][4] A loss-of-function mutation in TNFRSF11B (osteoprotegerin gene) has been identified in families with early-onset osteoarthritis and chondrocalcinosis.[1][4] Genetic testing for ANKH and TNFRSF11B variants should be considered in patients with onset before age 50–60 years or a strong family history.[4]

Metabolic associations affecting interpretation

Because hyperparathyroidism, hemochromatosis, hypomagnesemia, and hypophosphatasia are established causes of CPPD, identification of CPPD in the TMJ should trigger metabolic evaluation — the arthropathy may be the presenting sign of an undiagnosed systemic condition.[1]